The benefits and risks of alemtuzumab in multiple sclerosis

被引：0
|
作者：
Ontaneda, Daniel [1 ]
Cohen, Jeffrey A. [1 ]
机构：
[1] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Neurol Inst, Cleveland, OH 44106 USA
来源：
EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2013年 / 9卷 / 03期
关键词：
alemtuzumab; efficacy; multiple sclerosis; risk; THERAPEUTIC LYMPHOCYTE DEPLETION; DISEASE;
D O I：
10.1586/ECI.13.1
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：189 / 191
页数：3
相关论文
共 50 条
  • [41] Autologous haematopoietic stem-cell transplantation in multiple sclerosis: benefits and risks
    E. Capello
    L. Vuolo
    F. Gualandi
    M. T. Van Lint
    L. Roccatagliata
    L. Bonzano
    M. Pardini
    A. Uccelli
    Gianluigi Mancardi
    [J]. Neurological Sciences, 2009, 30 : 175 - 177
  • [42] Drug safety evaluation of alemtuzumab for multiple sclerosis
    Willis, Mark
    Robertson, Neil P.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2014, 13 (08) : 1115 - 1124
  • [43] Multiple Sclerosis Long Term Effectiveness of Alemtuzumab
    Ameri, Abdol A.
    [J]. AKTUELLE NEUROLOGIE, 2016, 43 (02) : 145 - 145
  • [44] Autologous haematopoietic stem-cell transplantation in multiple sclerosis: benefits and risks
    Capello, E.
    Vuolo, L.
    Gualandi, F.
    Van Lint, M. T.
    Roccatagliata, L.
    Bonzano, L.
    Pardini, M.
    Uccelli, A.
    Mancardi, Gianluigi
    [J]. NEUROLOGICAL SCIENCES, 2009, 30 : 175 - 177
  • [45] Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis
    Sorensen, Per Soelberg
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2011, 311 : S29 - S34
  • [46] Sarcoidosis following alemtuzumab treatment for multiple sclerosis
    Willis, Mark D.
    Hope-Gill, Ben
    Flood-Page, Patrick
    Joseph, Fady
    Needham, Ed
    Jones, Joanne
    Coles, Alasdair
    Robertson, Neil P.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (13) : 1779 - 1782
  • [47] Alemtuzumab is a new drug based on monoclonal antibodies for treatment multiple sclerosis: treatment possibilities and risks (review)
    Khasayeva, M. A.
    Gorokhova, T. V.
    Boyko, A. N.
    Gusev, E. I.
    [J]. ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2013, 113 (02) : 87 - +
  • [48] Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
    Ruck, Tobias
    Bittner, Stefan
    Wiendl, Heinz
    Meuth, Sven G.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (07) : 16414 - 16439
  • [49] Melanoma following treatment with alemtuzumab for multiple sclerosis
    Pace, A. A.
    Zajicek, J. P.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (04) : E70 - E71
  • [50] Alemtuzumab and Multiple Sclerosis Another Note of Caution
    Hohlfeld, Reinhard
    Kuempfel, Tania
    [J]. JAMA NEUROLOGY, 2016, 73 (06) : 637 - 638
12345